Elon Musk, owner of Neuralink, announced that the first human patient implanted with a Neuralink brain-machine device is "recovering well." In a January 29 post, Musk mentioned that the implant was successfully received on January 28, with promising preliminary results indicating the detection of neuronal spikes. Neuralink's brain implants aim to assist individuals with severe injuries or paralysis in interacting with phones or computers using their thoughts. The first product from Neuralink, named Telepathy, is envisioned to enhance communication speed for individuals like Stephen Hawking.
Neuralink initiated its first human clinical trial application in September 2023 after obtaining approval from the U.S. Food and Drug Administration in May 2023 for the Precision Robotic Implantable Brain-Computer Interface (PRIME) study. The original objective of the PRIME study was to develop a successful brain-computer interface (BCI) enabling individuals to control a computer cursor or keyboard using their thoughts. The implantation process involves a small incision in the patient's skull, and a surgical robot places the Neuralink device, consisting of ultra-thin and flexible wires, in the brain region controlling movement intentions.
Once implanted, the device, seemingly invisible, acts as a recording and transmission tool, wirelessly sending data to an app that decodes the patient's thoughts into digital movements on the device. However, Neuralink's safety procedures have faced criticism from regulators, prompting four U.S. lawmakers to request an SEC investigation into Elon Musk's alleged false safety claims about Neuralink implants. Musk's statement that "no monkeys have died from Neuralink implants," made in a now-deleted post from September 10, 2023, has drawn accusations of deliberate misrepresentation.
The Physicians Committee for Responsible Medicine, in a letter to the SEC's Enforcement Division on September 20, claimed that at least 12 baby monkeys were euthanized due to health problems linked directly to Neuralink implants. The incident has fueled concerns and calls for a closer examination of the safety protocols associated with Neuralink's groundbreaking brain-machine interface technology.
